CN101558075A - 5-[4-(氮杂环丁烷-3-基氧基)-苯基]-2-苯基-5H-噻唑并[5,4-c]吡啶-4-酮衍生物及其作为MCH受体拮抗剂的用途 - Google Patents

5-[4-(氮杂环丁烷-3-基氧基)-苯基]-2-苯基-5H-噻唑并[5,4-c]吡啶-4-酮衍生物及其作为MCH受体拮抗剂的用途 Download PDF

Info

Publication number
CN101558075A
CN101558075A CNA200780046086XA CN200780046086A CN101558075A CN 101558075 A CN101558075 A CN 101558075A CN A200780046086X A CNA200780046086X A CN A200780046086XA CN 200780046086 A CN200780046086 A CN 200780046086A CN 101558075 A CN101558075 A CN 101558075A
Authority
CN
China
Prior art keywords
phenyl
thiazole
azetidine
compound
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200780046086XA
Other languages
English (en)
Chinese (zh)
Inventor
K·M·加迪尼尔
D·J·加梅内
E·J·亨布尔
M·布鲁纳夫斯
H·J·塞克尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39204735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101558075(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN101558075A publication Critical patent/CN101558075A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
CNA200780046086XA 2006-12-14 2007-11-15 5-[4-(氮杂环丁烷-3-基氧基)-苯基]-2-苯基-5H-噻唑并[5,4-c]吡啶-4-酮衍生物及其作为MCH受体拮抗剂的用途 Pending CN101558075A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87001106P 2006-12-14 2006-12-14
US60/870,011 2006-12-14

Publications (1)

Publication Number Publication Date
CN101558075A true CN101558075A (zh) 2009-10-14

Family

ID=39204735

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200780046086XA Pending CN101558075A (zh) 2006-12-14 2007-11-15 5-[4-(氮杂环丁烷-3-基氧基)-苯基]-2-苯基-5H-噻唑并[5,4-c]吡啶-4-酮衍生物及其作为MCH受体拮抗剂的用途

Country Status (16)

Country Link
US (1) US8049013B2 (cg-RX-API-DMAC7.html)
EP (1) EP2089397B1 (cg-RX-API-DMAC7.html)
JP (1) JP5269804B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090082484A (cg-RX-API-DMAC7.html)
CN (1) CN101558075A (cg-RX-API-DMAC7.html)
AR (1) AR064127A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007334171A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0721086A2 (cg-RX-API-DMAC7.html)
CA (1) CA2671765A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007003480A1 (cg-RX-API-DMAC7.html)
EA (1) EA015559B1 (cg-RX-API-DMAC7.html)
ES (1) ES2392276T3 (cg-RX-API-DMAC7.html)
MX (1) MX2009006319A (cg-RX-API-DMAC7.html)
PE (1) PE20081572A1 (cg-RX-API-DMAC7.html)
TW (1) TW200831082A (cg-RX-API-DMAC7.html)
WO (1) WO2008076562A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107400044A (zh) * 2013-01-25 2017-11-28 中央硝子株式会社 α,α‑二氟乙醛的制造方法
CN108997138A (zh) * 2018-08-17 2018-12-14 济南和润化工科技有限公司 一种无溶剂催化氢化法生产对氟苯胺的方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
AU2010332819B2 (en) 2009-12-18 2014-02-27 Janssen Pharmaceutica Nv Bicyclic thiazoles as allosteric modulators of mGluR5 receptors
EP2513117B1 (en) 2009-12-18 2013-08-28 Janssen Pharmaceutica, N.V. Bicyclic thiazoles as allosteric modulators of mglur5 receptors
EA201291384A1 (ru) * 2010-07-06 2013-07-30 Астразенека Аб Терапевтические агенты 976
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
CN116082225A (zh) * 2016-08-08 2023-05-09 北京康蒂尼药业股份有限公司 一种羟尼酮的制备方法
CN107698498A (zh) * 2016-08-08 2018-02-16 罗楹 一种羟尼酮的制备方法
US20260152484A1 (en) * 2021-11-09 2026-06-04 Vigil Neuroscience, Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124627D0 (en) * 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
ATE446962T1 (de) * 2004-12-17 2009-11-15 Lilly Co Eli Thiazolopyridinon-derivate als mch- rezeptorantagonisten

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107400044A (zh) * 2013-01-25 2017-11-28 中央硝子株式会社 α,α‑二氟乙醛的制造方法
CN107400044B (zh) * 2013-01-25 2020-08-07 中央硝子株式会社 α,α-二氟乙醛的制造方法
CN108997138A (zh) * 2018-08-17 2018-12-14 济南和润化工科技有限公司 一种无溶剂催化氢化法生产对氟苯胺的方法

Also Published As

Publication number Publication date
WO2008076562A1 (en) 2008-06-26
JP5269804B2 (ja) 2013-08-21
EA015559B1 (ru) 2011-08-30
EP2089397A1 (en) 2009-08-19
CA2671765A1 (en) 2008-06-26
TW200831082A (en) 2008-08-01
CL2007003480A1 (es) 2008-07-11
EP2089397B1 (en) 2012-08-29
MX2009006319A (es) 2009-12-14
JP2010513292A (ja) 2010-04-30
KR20090082484A (ko) 2009-07-30
AU2007334171A1 (en) 2008-06-26
BRPI0721086A2 (pt) 2014-02-25
US8049013B2 (en) 2011-11-01
ES2392276T3 (es) 2012-12-07
AR064127A1 (es) 2009-03-11
EA200970582A1 (ru) 2010-02-26
PE20081572A1 (es) 2008-12-27
US20100069352A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
JP5623289B2 (ja) ウイルスポリメラーゼインヒビター
CN111377917B (zh) 杂环类化合物、中间体、其制备方法及应用
CN111225915B (zh) 作为pad抑制剂的咪唑并吡啶化合物
JP5269804B2 (ja) 新規なmch受容体拮抗薬
AU2014270152B9 (en) Heterocyclic derivates
JP2026021310A (ja) 融合三環式kras阻害剤
CN101080411B (zh) 作为mch受体拮抗剂的噻唑并吡啶酮衍生物
TWI500622B (zh) 雜環衍生物
CN119101049A (zh) 用于迅速加速性纤维肉瘤多肽的靶向降解的多环化合物和方法
CN1469878A (zh) 用作hiv整合酶抑制剂的氮杂和多氮杂萘基羧酰胺类化合物
CN101360743A (zh) 作为ppar调节剂的多环的1,2,3,4-四氢-异喹啉衍生物和包含它们的组合物
CN102164916A (zh) 选择性调节cb2受体的磺酰基化合物
MX2010013555A (es) Agonistas del receptor de esfingosin 1-fosfato 1 y uso de los mismos.
JP5643290B2 (ja) Hiv複製の阻害薬
TW202000659A (zh) 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
JP2010535155A (ja) ウイルスポリメラーゼ阻害剤
WO2024124287A1 (en) Compounds for treating viral infection
JP2012504556A (ja) ウイルスポリメラーゼ阻害剤
CN111356695B (zh) 新的三环化合物
TWI783480B (zh) 用於抑制cdk7之化合物
JP2024028642A (ja) カンナビノイド受容体部分アゴニストとしてのインダゾール誘導体
CN114845996A (zh) 一种含苯环的化合物及其应用
CN109415366A (zh) 新型[1,2,3]三唑并[4,5-d]嘧啶衍生物
CN109311895A (zh) 新型[1,2,3]三唑并[4,5-d]嘧啶衍生物
CN109265471A (zh) Fxr受体激动剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20091014

C20 Patent right or utility model deemed to be abandoned or is abandoned